Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HOVON 156 AML: gilteritinib versus midostaurin with intensive chemotherapy in newly diagnosed FLT3-mutated AML or MDS-EB2
NL-OMON60326Phase 2Active, not recruiting
- Sponsor
- HOVON
- Start
- Dec 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in acute myeloid leukemia (AML) and Myelodysplastic neoplasm with increased blasts 2 (MDS-IB2) comparing Gilteritinib + chemotherapy with Midostaurin + chemotherapy (2 arms). Primary endpoint: Overall survival. Started Dec 2019; status: active, not recruiting.
02
Drugs
gilteritinibmidostaurin
03
Conditions
acute myeloid leukemia (AML)Myelodysplastic neoplasm with increased blasts 2 (MDS-IB2)
Beyond the preview
Go deeper on NL-OMON60326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60326.